InvestorsHub Logo
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

Re: None

Monday, 08/13/2007 6:26:25 AM

Monday, August 13, 2007 6:26:25 AM

Post# of 19309
How likely is the U.S. ATryn trial to succeed?

Success is likely, IMO, for several reasons:

1. The unmet medical need for ATryn in the U.S. is much greater than in Europe because there is only one approved plasma-derived antithrombin product (Thrombate from Talecris) and its supply is small and unreliable (#msg-20966468). By comparison, Europe has a reliable source of plasma-derived antithrombin from several manufacturers.

2. Compared to the phase-3 trial that got ATryn approved in Europe, the U.S. phase-3 trial includes more than twice as many patients treated with ATryn and it has a control arm (#msg-5609005).

3. Forty-five percent (14/31) of the patents in the ATryn arm of the U.S. phase-3 trial are already known to have been treated successfully because they are the same 14 patients who comprised the data set that led to ATryn approval in the EU. This is like a baseball player stepping up to home plate with a count of two balls and no strikes!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.